Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC73883 ALK-IN-28 ALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK). ALK-IN-28 Chemical Structure
  3. GC35289 ALK-IN-5 ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK), with an IC50 of 2.9 nM. ALK-IN-5 Chemical Structure
  4. GC35290 ALK-IN-6 ALK-IN-6 (compound 11) is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK), with IC50 values of 71 nM, 18.72 nM and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L, respectively. ALK-IN-6 Chemical Structure
  5. GC64398 Almonertinib mesylate

    HS-10296 mesylate

     Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer. Almonertinib mesylate Chemical Structure
  6. GC32127 Alofanib (RPT835)

    RPT835

     Alofanib (RPT835) (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Alofanib (RPT835) Chemical Structure
  7. GC16604 Altiratinib

    DCC-2701

     c-MET/TIE-2/VEGFR inhibitor Altiratinib Chemical Structure
  8. GC11134 ALW-II-41-27

    Eph receptor tyrosine kinase inhibitor;

     ALW-II-41-27 is an Eph family tyrosine kinase inhibitor with an IC50 of 11 nM to inhibit Eph2. ALW-II-41-27 Chemical Structure
  9. GC68647 ALW-II-49-7

    ALW-II-49-7 is a selective inhibitor of EphB2 with an intracellular EC50 of 40 nM.

     ALW-II-49-7 Chemical Structure
  10. GC15655 AMG 337 MET inhibitor AMG 337 Chemical Structure
  11. GC14974 AMG 925 FLT3/CDK4 inhibitor,potent and selective AMG 925 Chemical Structure
  12. GC35315 AMG 925 HCl AMG 925 HCl is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively. AMG 925 HCl Chemical Structure
  13. GC12600 AMG-208 C-Met inhibitor,potent and highly selective AMG-208 Chemical Structure
  14. GC11481 AMG-458

    AMG 458; AMG458

     Potent c-Met inhibitor AMG-458 Chemical Structure
  15. GC17669 AMG-47A destabilizer of the KRAS oncoprotein AMG-47A Chemical Structure
  16. GC67749 Amivantamab

    JNJ-61186372

    Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity

     Amivantamab Chemical Structure
  17. GC64015 AMP-945

    AMP-945

     AMP-945 is an inhibitor of the enzyme focal adhesion kinase (FAK). AMP-945 Chemical Structure
  18. GC16391 Amuvatinib (MP-470, HPK 56)

    HPK56, MP470

     A multi-targeted RTK inhibitor Amuvatinib (MP-470, HPK 56) Chemical Structure
  19. GC33362 Amuvatinib hydrochloride (MP470 hydrochloride)

    MP470 hydrochloride; HPK 56 hydrochloride

     Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity. Amuvatinib hydrochloride (MP470 hydrochloride) Chemical Structure
  20. GC11486 ANA 12 TrkB receptor antagonist ANA 12 Chemical Structure
  21. GC74504 Anbenitamab

    KN-026

     Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab Chemical Structure
  22. GC45677 Anlotinib (hydrochloride) A neuropeptide with diverse biological activities Anlotinib (hydrochloride) Chemical Structure
  23. GC70625 AnnH31 AnnH31 is a Dyrk1A inhibitor (IC50: 81 nM). AnnH31 Chemical Structure
  24. GC70992 Ansornitinib Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib Chemical Structure
  25. GC74505 Anumigilimab

    CSL-324

     Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab Chemical Structure
  26. GC17283 AP26113

    Brigatinib

     AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. AP26113 Chemical Structure
  27. GC14292 Apatinib Mesylate

    YN968D1

     Apatinib Mesylate blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization. Apatinib Mesylate Chemical Structure
  28. GC49799 Apatinib-d8 An internal standard for the quantification of apatinib Apatinib-d8 Chemical Structure
  29. GC65515 Aprutumab Aprutumab?(BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has?the?potential?for?solid tumors research. Aprutumab Chemical Structure
  30. GC60592 APS6-45 APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity. APS6-45 Chemical Structure
  31. GC73077 ARI-1 ARI-1 is an inhibitor of receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitor. ARI-1 Chemical Structure
  32. GC12478 ARRY-380

    ARRY380; ARRY 380

     ARRY-380, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2. ARRY-380 Chemical Structure
  33. GC60601 ARRY-382 ARRY-382 Chemical Structure
  34. GC46013 AS-2444697 (hydrochloride) AS-2444697 (hydrochloride) is an orally active IRAK-4 inhibitor with an IC50 of 21 nM. AS-2444697 (hydrochloride) Chemical Structure
  35. GC32703 Asciminib (ABL001)

    ABL001

     Asciminib (ABL001) (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib (ABL001) Chemical Structure
  36. GC64462 Asciminib hydrochloride Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib hydrochloride Chemical Structure
  37. GC62402 ASK120067

    ASK120067

     ASK120067 (ASK120067) is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research ofnon-small cell lung cancer (NSCLC). ASK120067 Chemical Structure
  38. GC72825 ASN06917370 ASN06917370 is a former orphan receptor GPR17 ligand for the study of neurodegenerative diseases. ASN06917370 Chemical Structure
  39. GC14446 ASP3026

    ASP 3026;ASP-3026

     An ALK inhibitor ASP3026 Chemical Structure
  40. GC34476 ASP5878 ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity. ASP5878 Chemical Structure
  41. GC10914 AST 487

    NVP-AST 487

     A multi-kinase inhibitor AST 487 Chemical Structure
  42. GC11691 AST-1306

    AST1306; AST 1306

     AST-1306 (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 is an anilino-quinazoline compound and has anti-cancer activity. AST-1306 Chemical Structure
  43. GC15669 AST-1306 TsOH

    Allitinib

     AST-1306 TsOH (AST-1306 (TsOH)) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 TsOH also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 TsOH is an anilino-quinazoline compound and has anti-cancer activity AST-1306 TsOH Chemical Structure
  44. GC33096 AST2818 mesylate

    AST2818

     Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of EGFR. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib (Furmonertinib) mesylate has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC). AST2818 mesylate Chemical Structure
  45. GC62481 AST5902 trimesylate AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an EGFR inhibitor. AST5902 trimesylate Chemical Structure
  46. GC35413 Astragaloside VI Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing. Astragaloside VI Chemical Structure
  47. GC10638 AT9283 A broad spectrum kinase inhibitor AT9283 Chemical Structure
  48. GC62499 ATH686 ATH686 is a potent, selective and ATP-competitive FLT3 inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects. ATH686 Chemical Structure
  49. GC35435 AV-412

    MP-412

     A dual inhibitor of EGFR and HER2 AV-412 Chemical Structure
  50. GC35436 AV-412 free base

    MP-412 free base

     AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively. AV-412 free base Chemical Structure
  51. GC19074 Avapritinib

    Avapritinib

     Avapritinib is a potent and selective exon 17 mutant KIT kinase inhibitor with IC50 of 0.27 nM for KIT D816V. Avapritinib Chemical Structure
  52. GC42884 Avitinib

    AC0010

    Avitinib is a pyrrolopyrimidine-based, irreversible inhibitor of the epidermal growth factor receptor (EGFR).

     Avitinib Chemical Structure
  53. GC19044 Avitinib maleate

    A pyrrolopyrimidine-based irreversible EGFR inhibitor

     Avitinib maleate Chemical Structure
  54. GC64683 AVJ16 AVJ16 is a member of the insulin-like growth factor 2 mRNA-binding protein family. AVJ16 regulates protein translation by binding to the mRNAs of certain genes. AVJ16 Chemical Structure
  55. GC72392 Axatilimab Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab Chemical Structure
  56. GC12216 Axitinib (AG 013736)

    AG 013736

     Axitinib (AG 013736) is an orally active specific vascular endothelial growth factor receptor (VEGFR) inhibitor that targets VEGFR-1, VEGFR-2, and VEGFR-3 with IC50 values of 0.1nM, 0.2nM, and 0.1-0.3nM, respectively. Axitinib (AG 013736) Chemical Structure
  57. GC42887 Axitinib Sulfoxide Axitinib sulfoxide is a major inactive metabolite of the tyrosine kinase inhibitor axitinib. Axitinib Sulfoxide Chemical Structure
  58. GC46899 Axitinib-13C-d3

    AG-013736-13C-d3

     An internal standard for the quantification of axitinib Axitinib-13C-d3 Chemical Structure
  59. GC62185 Axitinib-d3

    AG-013736-d3

     Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively. Axitinib-d3 Chemical Structure
  60. GC73370 AXL-IN-13 AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 Chemical Structure
  61. GC17045 AXL1717

    AXL 1717, NSC 36407, Picropodophyllin, PPP

     A potent and selective inhibitor of IGF-1R AXL1717 Chemical Structure
  62. GC50221 AZ Dyrk1B 33 Potent and selective Dyrk1B kinase inhibitor AZ Dyrk1B 33 Chemical Structure
  63. GC33090 AZ-23 (AZ23) AZ-23 (AZ23) is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC50s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively. AZ-23 (AZ23) Chemical Structure
  64. GC64071 AZ14145845 AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy. AZ14145845 Chemical Structure
  65. GC33054 AZ1495 An oral active inhibitor of IRAK4 AZ1495 Chemical Structure
  66. GC17654 AZ191 DYRK1B inhibitor,potent and selective AZ191 Chemical Structure
  67. GC12955 AZ5104 EGFR inhibitor AZ5104 Chemical Structure
  68. GC33072 AZ7550 AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM. AZ7550 Chemical Structure
  69. GC34287 AZ7550 hydrochloride AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM. AZ7550 hydrochloride Chemical Structure
  70. GC34414 AZ7550 Mesylate (AZ7550 trimesylate salt) AZ7550 Mesylate (AZ7550 trimesylate salt) Chemical Structure
  71. GC31880 AZD-0284 AZD-0284 is a selective inverse agonist of the nuclear receptor RORγ. AZD-0284 Chemical Structure
  72. GC14189 AZD-3463

    ALK/IGF1R inhibitor

     ALK/IGF1R inhibitor AZD-3463 Chemical Structure
  73. GC16308 AZD-9291

    osimertinib

     AZD-9291 (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. AZD-9291 overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. AZD-9291 Chemical Structure
  74. GC16698 AZD-9291 mesylate AZD-9291 mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. AZD-9291 mesylate Chemical Structure
  75. GC17959 AZD2932 inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit AZD2932 Chemical Structure
  76. GC33027 AZD3229 An inhibitor of c-Kit-driven cell proliferation AZD3229 Chemical Structure
  77. GC33246 AZD3229 Tosylate AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. AZD3229 Tosylate Chemical Structure
  78. GC13143 AZD3759

    AZD3759

     AZD3759 (AZD3759) is a potent, orally active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively. AZD3759 Chemical Structure
  79. GC14005 AZD4547

    AZD 4547;AZD-4547

     FGFR inhibitor AZD4547 Chemical Structure
  80. GC19404 AZD7507

    AZD7507 is a potent and selective CSF-1R inhibitor (32 nM cell activity)

     AZD7507 Chemical Structure
  81. GC13761 AZD8931 (Sapitinib)

    Sapitinib

     AZD8931 (Sapitinib) (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC50s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively. AZD8931 (Sapitinib) Chemical Structure
  82. GC32875 AZM475271 (M475271)

    M475271

     AZM475271 (M475271) is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2. AZM475271 (M475271) Chemical Structure
  83. GC18580 B355252 A neuroprotective agent B355252 Chemical Structure
  84. GC35462 Bafetinib

    INNO-406

    Bcr-Abl/Lyn tyrosine kinase inhibitor

     Bafetinib Chemical Structure
  85. GC74510 Bafisontamab

    EMB-01

     Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity. Bafisontamab Chemical Structure
  86. GC74512 Barecetamab

    ISU-104

     Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab Chemical Structure
  87. GC68727 Barzolvolimab

    CDX 0159

    Barzolvolimab (CDX 0159) is a humanized monoclonal antibody against KIT IgG1. Barzolvolimab specifically and effectively inhibits the activation of KIT. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria.

     Barzolvolimab Chemical Structure
  88. GC64377 Batatasin III Batatasin III, a stilbenoid, inhibits cancer migration and invasion by suppressing epithelial to mesenchymal transition (EMT) and FAK-AKT signals. Batatasin III has anti-cancer activities. Batatasin III Chemical Structure
  89. GC74513 Batiraxcept

    AVB-S6-500

     Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept Chemical Structure
  90. GC11726 BAW2881 (NVP-BAW2881)

    NVP-BAW 2881

     BAW2881 (NVP-BAW2881) (BAW2881) is a potent and selective VEGFR2 inhibitor with an IC50 of 4 nM. BAW2881 (NVP-BAW2881) Chemical Structure
  91. GC64302 BAY 2476568 BAY 2476568 is a potent and selective EGFR inhibitor, with IC50s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG). BAY 2476568 Chemical Structure
  92. GC16389 BAY 61-3606 A Syk inhibitor BAY 61-3606 Chemical Structure
  93. GC12136 BAY 61-3606 dihydrochloride

    BAY61-3606 dihydrochloride;BAY 61-3606

     BAY 61-3606 dihydrochloride Chemical Structure
  94. GC45830 BAY-1125976 An allosteric inhibitor of Akt1/2 BAY-1125976 Chemical Structure
  95. GC19062 BBT594

    NVP-BBT594

     BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment. BBT594 Chemical Structure
  96. GC33343 BCR-ABL-IN-1 BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia. BCR-ABL-IN-1 Chemical Structure
  97. GC33368 BCR-ABL-IN-2 BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. BCR-ABL-IN-2 Chemical Structure
  98. GC73614 BCR-ABL-IN-8 BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor containing trimethoxy group. BCR-ABL-IN-8 Chemical Structure
  99. GC12186 BDNF (human) activator of TrkB and p75 neurotrophin receptors BDNF (human) Chemical Structure
  100. GC60629 BDTX-189

    BDTX-189

     BDTX-189 (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. BDTX-189 shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity. BDTX-189 Chemical Structure
  101. GC74436 Becotatug

    JMT-101

     Becotatug (JMT-101) is an IgG1 antibody targeting EGFR that can also be conjugated to Afatinib and Osimertinib as a synthetic ADC. Becotatug Chemical Structure

Items 101 to 200 of 1359 total

per page
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5

Set Descending Direction